Literature DB >> 34642799

Gastroparesis with concomitant gastrointestinal dysmotility is not a contraindication for per-oral pyloromyotomy (POP).

Abhiram Kondajji1,2, Michael Klingler3, Chao Tu4, Rebecca Kelley5, Kevin El-Hayek6, John Rodriquez7, Michael Cline3, Alisan Fathalizadeh3, Matthew Allemang3.   

Abstract

INTRODUCTION: Per-oral pyloromyotomy (POP or G-POEM) provides significant short-term improvements in symptoms and objective emptying for patients with medically refractory gastroparesis, but it is unclear if patients with gastroparesis and co-existing dysmotility (small bowel or colonic delay) also benefit. In this study, we used wireless motility capsule (WMC) data to measure outcomes in patients with isolated gastroparesis (GP) and gastroparesis with co-existing dysmotility (GP + Dys) who underwent POP.
METHODS: We retrospectively analyzed patients who had POP and completed WMC data during their evaluation of intestinal dysmotility. WMC data were reviewed to identify patients who demonstrated isolated GP or GP + Dys. Each patient's pre-op and post-op Gastroparesis Cardinal Symptom Index (GCSI) and 4-h solid-phase scintigraphy gastric emptying studies (GES) scores were compared to evaluate improvement.
RESULTS: Of the entire cohort (n = 73), 89% were female with a mean age of 47.0 ± 15.0 years old. Gastroparesis etiologies were divided among idiopathic (54.8%), diabetic (26%), postsurgical (8.2%), autoimmune (5.5%), and multifactorial (5.5%). Forty-one patients (56%) had GP and 32 patients (44%) had GP + Dys. GCSI improved after POP whether the patient had isolated GP (- 12.31, p < 0.001) or GP + Dys (- 9.58, p < 0.001); however, there was no significant difference in total GCSI improvement between the two groups. A subset of patients had postoperative GES available (n = 47). In the isolated GP and GP + Dys cohorts, 15/28 (54%) and 12/19 (63%) patients had normal post-op 4-h GES, respectively, but no statistical difference between the two groups.
CONCLUSION: Patients with medically refractory gastroparesis with and without concomitant gastrointestinal dysmotility show short-term subjective and objective improvement after POP. Concomitant small bowel or colonic dysmotility should not deter physicians from offering POP in carefully selected patients with gastroparesis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gastroparesis; Intestinal dysmotility; Pyloromyotomy; Wireless motility capsule

Mesh:

Year:  2021        PMID: 34642799     DOI: 10.1007/s00464-021-08756-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  21 in total

Review 1.  Epidemiology and Pathophysiology of Gastroparesis.

Authors:  Baha Moshiree; Michael Potter; Nicholas J Talley
Journal:  Gastrointest Endosc Clin N Am       Date:  2019-01

Review 2.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.

Authors:  Henry P Parkman; William L Hasler; Robert S Fisher
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 3.  Gastroparesis: current diagnostic challenges and management considerations.

Authors:  Shamaila Waseem; Baharak Moshiree; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

4.  Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL.

Authors:  Christine de la Loge; Elyse Trudeau; Patrick Marquis; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack; Dennis A Revicki; Anne M Rentz; Dominique Dubois
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

5.  Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis.

Authors:  Allen A Lee; Satish Rao; Linda A Nguyen; Baharak Moshiree; Irene Sarosiek; Michael I Schulman; John M Wo; Henry P Parkman; Gregory E Wilding; Richard W McCallum; William L Hasler; Braden Kuo
Journal:  Clin Gastroenterol Hepatol       Date:  2018-12-14       Impact factor: 11.382

6.  Clinical guideline: management of gastroparesis.

Authors:  Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

7.  Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index.

Authors:  D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack
Journal:  Aliment Pharmacol Ther       Date:  2003-07-01       Impact factor: 8.171

8.  Development and content validity of a gastroparesis cardinal symptom index daily diary.

Authors:  D A Revicki; M Camilleri; B Kuo; N J Norton; L Murray; A Palsgrove; H P Parkman
Journal:  Aliment Pharmacol Ther       Date:  2009-06-25       Impact factor: 8.171

9.  Validation of SmartPill® wireless motility capsule for gastrointestinal transit time: Intra-subject variability, software accuracy and comparison with video capsule endoscopy.

Authors:  H O Diaz Tartera; D-L Webb; A Kh Al-Saffar; M A Halim; G Lindberg; P Sangfelt; P M Hellström
Journal:  Neurogastroenterol Motil       Date:  2017-05-19       Impact factor: 3.598

10.  How to assess regional and whole gut transit time with wireless motility capsule.

Authors:  Yeong Yeh Lee; Askin Erdogan; Satish S C Rao
Journal:  J Neurogastroenterol Motil       Date:  2014-04-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.